These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30486477)
21. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions. Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897 [TBL] [Abstract][Full Text] [Related]
22. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells. Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676 [TBL] [Abstract][Full Text] [Related]
23. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs. Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707 [TBL] [Abstract][Full Text] [Related]
24. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542 [TBL] [Abstract][Full Text] [Related]
25. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769 [TBL] [Abstract][Full Text] [Related]
27. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant Pt Norman DJ; Gambardella A; Mount AR; Murray AF; Bradley M Angew Chem Int Ed Engl; 2019 Oct; 58(40):14189-14192. PubMed ID: 31397963 [TBL] [Abstract][Full Text] [Related]
28. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs. Markova L; Maji M; Kostrhunova H; Novohradsky V; Kasparkova J; Gibson D; Brabec V J Med Chem; 2024 Jun; 67(11):9745-9758. PubMed ID: 38819023 [TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. Margiotta N; Savino S; Marzano C; Pacifico C; Hoeschele JD; Gandin V; Natile G J Inorg Biochem; 2016 Jul; 160():85-93. PubMed ID: 26775068 [TBL] [Abstract][Full Text] [Related]
30. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance. Ma J; Li L; Yue K; Li Y; Liu H; Wang PG; Wang C; Wang J; Luo W; Xie S Bioorg Chem; 2020 Jun; 99():103768. PubMed ID: 32217375 [TBL] [Abstract][Full Text] [Related]
31. Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues. Huang X; Hua S; Huang R; Liu Z; Gou S; Wang Z; Liao Z; Wang H Eur J Med Chem; 2018 Mar; 148():1-25. PubMed ID: 29448138 [TBL] [Abstract][Full Text] [Related]
32. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug. Pathak RK; Dhar S Chemistry; 2016 Feb; 22(9):3029-36. PubMed ID: 26807548 [TBL] [Abstract][Full Text] [Related]
33. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug. Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261 [TBL] [Abstract][Full Text] [Related]
34. A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer. Pathak RK; Wen R; Kolishetti N; Dhar S Mol Cancer Ther; 2017 Apr; 16(4):625-636. PubMed ID: 28148716 [TBL] [Abstract][Full Text] [Related]
35. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. Chen F; Huang X; Wu M; Gou S; Hu W Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693 [TBL] [Abstract][Full Text] [Related]
36. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin. Shi H; Cheng Q; Yuan S; Ding X; Liu Y Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808 [TBL] [Abstract][Full Text] [Related]
37. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug. Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905 [TBL] [Abstract][Full Text] [Related]
38. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Petruzzella E; Braude JP; Aldrich-Wright JR; Gandin V; Gibson D Angew Chem Int Ed Engl; 2017 Sep; 56(38):11539-11544. PubMed ID: 28759160 [TBL] [Abstract][Full Text] [Related]
39. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance. Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870 [TBL] [Abstract][Full Text] [Related]
40. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin. Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]